Brokers Offer Predictions for ENTA FY2029 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Enanta Pharmaceuticals in a note issued to investors on Tuesday, December 24th. HC Wainwright analyst E. Arce anticipates that the biotechnology company will post earnings per share of ($6.62) for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($4.73) per share.

Several other equities research analysts also recently issued reports on the company. Robert W. Baird decreased their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday, November 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA opened at $6.00 on Wednesday. The company has a 50-day moving average price of $9.40 and a 200-day moving average price of $11.57. The stock has a market capitalization of $127.16 million, a P/E ratio of -1.09 and a beta of 0.49. Enanta Pharmaceuticals has a 1 year low of $5.70 and a 1 year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $17.99 million. During the same quarter in the previous year, the company posted ($1.33) EPS. The firm’s revenue was down 22.8% on a year-over-year basis.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now directly owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 13.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its stake in Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Barclays PLC increased its stake in shares of Enanta Pharmaceuticals by 294.2% during the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 20,478 shares during the period. Geode Capital Management LLC increased its position in Enanta Pharmaceuticals by 3.1% during the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares during the period. Krensavage Asset Management LLC raised its stake in Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in shares of Enanta Pharmaceuticals in the 3rd quarter valued at approximately $360,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.